Evaluation of EGFR inhibitor‐mediated acneiform skin toxicity within the double‐blind randomized EVITA trial: A thorough gender‐specific analysis using the WoMo score

Acne‐like skin reactions frequently occur in patients undergoing treatment with drugs inhibiting the epidermal growth factor receptor. Recently, the effects of vitamin K1 containing cream (Reconval K1) as prophylactic sk
Acne‐like skin reactions frequently occur in patients undergoing treatment with drugs inhibiting the epidermal growth factor receptor. Recently, the effects of vitamin K1 containing cream (Reconval K1) as prophylactic skin treatment in addition to doxycycline were explored in a double‐blind randomized phase II trial (EVITA) in patients with metastatic colorectal cancer receiving cetuximab. EVITA demonstrated a trend towards less severe skin rash in Reconval K1‐treated patients using the tripartite WoMo skin reaction grading score as a thorough tool for quantification of drug related skin reactions. This gender‐specific analysis of the EVITA trial evaluated the application of the WoMo score for assessment of epidermal growth factor receptor (EGFR)‐related skin toxicities according to treatment arm and gender. To show the robustness of results parametric and non‐parametric statistical analyses were conducted. All three parts of the WoMo score independently demonstrated the superiority of the treatment arm (Reconval K1) regarding a significant reduction in acneiform skin reactions in women. Men did not benefit from Reconval K1 cream at any time point in none of the WoMo score analyses. The treatment effect in women was confirmed by the use of skin rash categories based on the final WoMo overall score and mixed effect longitudinal multiple linear regression analysis. The WoMo score represents a sensitive tool for studies exploiting treatments against EGFR mediated acne‐like skin rash. Part C of the WoMo score seems to be sufficient for quantification of drug related skin toxicities in further studies. Standard WoMo skin reaction score values for future studies are provided.
show moreshow less

Metadaten
Author:Maria Gaiser, Sylvie Lorenzen, Kirsten Merx, Jörg Trojan, Janja Ocvirk, Thomas Jens Ettrich, Salah-Eddin al- Batran, Holger Schulz, Nils Homann, Hans‐Peter Feustel, Michael Schatz, Melanie Kripp, Nadine Schulte, Steffen Heeger, Soetkin Vlassak, Winfried Koch, Ralf‐Dieter Hofheinz
URN:urn:nbn:de:hebis:30:3-535503
DOI:http://dx.doi.org/10.1002/cam4.2132
ISSN:2045-7634
Pubmed Id:http://www.ncbi.nlm.nih.gov/pubmed?term=31199595
Parent Title (English):Cancer medicine
Publisher:Wiley
Place of publication:Hoboken, NJ
Document Type:Article
Language:English
Date of Publication (online):2019/06/14
Date of first Publication:2019/06/14
Publishing Institution:Universitätsbibliothek Johann Christian Senckenberg
Release Date:2020/07/29
Tag:EGFR inhibitor; WoMo score; acneiform skin toxicity; women
Volume:8
Issue:9
Pagenumber:7
First Page:4169
Last Page:4175
Note:
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
HeBIS PPN:467551464
Institutes:Medizin
Dewey Decimal Classification:610 Medizin und Gesundheit
Sammlungen:Universitätspublikationen
Licence (German):License LogoCreative Commons - Namensnennung 4.0

$Rev: 11761 $